Core Insights - Moleculin Biotech has enrolled the 45th subject in its pivotal Phase 2B/3 MIRACLE trial, evaluating Annamycin in combination with cytarabine for treating relapsed or refractory acute myeloid leukemia (R/R AML), marking a significant milestone for the company [1][2] - The upcoming interim data unblinding is expected in mid-2026 and is viewed as a potential inflection point for the company, with preliminary results indicating a 40% remission rate among the first 30 patients [2][3] Trial Progress - The MIRACLE trial is designed to evaluate AnnAraC across eight countries, with an initial dataset expected to include approximately 30 patients treated with AnnAraC and 15 patients in the control arm [2][4] - The trial's adaptive design aims to support a streamlined global registration pathway, integrating Phase 2B data into the Phase 3 portion, in line with regulatory guidance [4] Efficacy and Safety - Preliminary results from the trial show a composite complete remission rate of 40%, with 30% achieving complete remission and 10% achieving complete remission with partial hematologic recovery, despite many patients having previously failed venetoclax-based therapies [3][5] - The absence of cardiotoxicity in over 100 patients treated to date is a notable achievement for the company [2][5] Future Outlook - The company is advancing toward a total enrollment of 90 subjects, with the completion of Part A of the MIRACLE trial expected in Q3 2026 [2][4] - The successful outcomes from the trial could lead to a potential accelerated approval pathway based on the primary endpoint of complete remission [4][5]

Core Viewpoint - Moleculin Biotech, Inc. is actively participating in the 38th Annual ROTH Conference, showcasing its advancements in therapeutic candidates for hard-to-treat tumors and viruses [1]. Company Overview - Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapies for difficult-to-treat tumors and viruses. Its lead program, Annamycin, is designed to avoid multidrug resistance and cardiotoxicity associated with current anthracyclines [2]. Clinical Trials - The company has initiated the MIRACLE Trial (MB-108), a pivotal Phase 3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia (AML). The trial follows a successful Phase 1B/2 study and aims to de-risk the development pathway towards potential approval [3]. Additional Developments - Moleculin is also developing WP1066, an Immune/Transcription Modulator targeting various cancers, and has a portfolio of antimetabolites, including WP1122 for treating pathogenic viruses and certain cancer indications [4].

Core Viewpoint - Moleculin Biotech, Inc. is advancing its pivotal MIRACLE Study evaluating Annamycin in combination with cytarabine for patients with relapsed or refractory Acute Myeloid Leukemia, with promising results expected from the ongoing clinical trial [3][6]. Company Overview - Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses [5]. - The lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance and cardiotoxicity associated with current treatments [5]. Clinical Development - The MIRACLE Study (MB-108) is an adaptive Phase 3 trial designed with FDA input, involving an initial cohort of 45 patients [3][6]. - The study aims to evaluate the safety and efficacy of Annamycin in combination with cytarabine, with an interim unblinding planned after the initial cohort's treatment completion [3][6]. - The trial builds on positive outcomes from the earlier MB-106 Study, where Annamycin showed overall survival rates exceeding historical benchmarks in a challenging patient population [3]. Additional Pipeline - The company is also developing WP1066, an Immune/Transcription Modulator targeting various cancers, and WP1122, an antimetabolite for potential treatment of pathogenic viruses and certain cancer indications [7].

Group 1 - Moleculin Biotech, Inc. has entered into agreements for the immediate exercise of existing warrants to purchase up to 2,122,652 shares of common stock at an exercise price of $3.90 per share, expected to generate approximately $8.3 million in gross proceeds [1][4] - Roth Capital Partners is acting as the financial advisor for this transaction [2] - The company will issue new unregistered warrants for up to 6,367,956 shares, exercisable at the lesser of $3.90 or the lowest volume weighted average price during the next five trading days, subject to shareholder approval [3] Group 2 - The transaction is expected to close on or about February 20, 2026, pending customary closing conditions, with net proceeds intended for working capital and general corporate purposes [4] - The new warrants were offered in a private placement and have not been registered under the Securities Act of 1933, with the company agreeing to file a registration statement for the resale of shares [5] Group 3 - Moleculin Biotech is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses, with its lead program Annamycin targeting relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases [7][8] - The company has initiated the MIRACLE Trial, a pivotal Phase 3 trial evaluating Annamycin in combination with cytarabine for the treatment of relapsed or refractory acute myeloid leukemia, following a successful Phase 1B/2 study [8] - Additionally, the company is developing WP1066, an immune/transcription modulator targeting various cancers, and has a portfolio of antimetabolites including WP1122 for potential treatment of pathogenic viruses [9]

Core Insights - The preliminary blinded complete remission (CR) rate in the MIRACLE trial shows a 67% improvement over historical cytarabine response rates, indicating a significant advancement in the treatment of acute myeloid leukemia (AML) [1][3] - Approximately 35% of subjects treated so far are failures from the ventoclax regimen, highlighting the challenging nature of this patient population [1][3] - The company is on track to treat the first 45 subjects by Q1 2026, with unblinding of data expected thereafter [1][8] Trial Progress and Efficacy - The MIRACLE trial has reported a preliminary composite complete remission (CRc) rate of 40% among the first 30 subjects, consisting of a 30% complete remission (CR) rate and a 10% complete remission with partial hematological recovery (CRh) [2] - The trial is designed as a Phase 2B/3, global multi-center, randomized, double-blind, placebo-controlled study, combining data from both phases to measure primary efficacy endpoints [5] - The first unblinding of preliminary efficacy data is expected to yield results from approximately 30 subjects treated with Annamycin in combination with cytarabine and 15 subjects treated with cytarabine plus placebo [5][8] Recruitment and Future Steps - The company has encountered higher than expected disqualifications among applicants, indicating a significant unmet medical need among relapsed/refractory AML patients [6] - Recruitment efforts are ongoing, with a focus on improving participation in the US, while European recruitment has been robust [7] - The second group of 45 subjects in Part A is expected to be fully recruited by Q3 2026, with unblinding anticipated in the second half of 2026 [8] Regulatory Status and Market Potential - Annamycin has received Fast Track Status and Orphan Drug Designation from the FDA for the treatment of relapsed or refractory AML, along with patent protection extending to 2040, potentially to 2045 [10] - The company believes Annamycin could offer a new treatment avenue for patients battling AML, especially given its lack of cardiotoxicity compared to current therapies [3][11]

Core Viewpoint - Moleculin Biotech, Inc. has received a notice of allowance for a patent in Japan related to the preparation of liposomal Annamycin, which is expected to enhance its intellectual property position and support the development of its non-cardiotoxic therapy for acute myeloid leukemia [1][2][3] Group 1: Patent and Intellectual Property - The Japan Patent Office has allowed claims for a patent application covering methods for reconstituting liposomal Annamycin, ensuring consistent dosing and stability for intravenous administration [2] - This patent allowance complements existing U.S. and European patent protections, with additional applications pending in major jurisdictions worldwide [2][3] Group 2: Product Development and Clinical Trials - Annamycin, also known as naxtarubicin, is being developed for the treatment of relapsed or refractory acute myeloid leukemia (AML) and is positioned to be the first non-cardiotoxic anthracycline approved for clinical use [2][4] - The company has initiated the MIRACLE Trial (MB-108), a pivotal Phase 3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory AML [5] - Annamycin has received Fast Track Status and Orphan Drug Designation from the FDA for relapsed or refractory AML, as well as Orphan Drug Designation from the EMA [3][5] Group 3: Company Overview - Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapies for hard-to-treat tumors and viruses, with Annamycin as its lead program [4][6] - The company is also developing WP1066, an immune/transcription modulator targeting various cancers, and has a portfolio of antimetabolites for potential treatment of pathogenic viruses and certain cancer indications [6]

Core Insights - Moleculin Biotech, Inc. has launched a new platform called CEO Corner to enhance communication with investors and stakeholders, providing deeper insights into corporate developments and clinical progress [1][2] Company Overview - Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses [5] - The lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance and cardiotoxicity, currently in development for relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases [5] Clinical Trials - The company has initiated the MIRACLE Trial (MB-108), a pivotal Phase 3 trial evaluating Annamycin in combination with cytarabine for treating relapsed or refractory AML [6] - Following a successful Phase 1B/2 study, the company believes it has de-risked the development pathway for Annamycin towards potential approval for AML treatment [6] Additional Pipeline Developments - Moleculin is also developing WP1066, an immune/transcription modulator targeting brain tumors and pancreatic cancers, and has a portfolio of antimetabolites including WP1122 for treating pathogenic viruses and certain cancer indications [7]

Company Overview - Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses [3] - The lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance and cardiotoxicity associated with current treatments [3] - Annamycin is in development for relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases [3] Clinical Trials - The company has initiated the MIRACLE Trial (MB-108), a pivotal Phase 3 trial evaluating Annamycin in combination with cytarabine for treating relapsed or refractory AML [4] - Following a successful Phase 1B/2 study (MB-106) and FDA input, the company believes it has de-risked the development pathway for Annamycin's potential approval [4] Additional Pipeline - Moleculin is also developing WP1066, an Immune/Transcription Modulator targeting brain tumors and pancreatic cancers by inhibiting oncogenic transcription factors [5] - The pipeline includes antimetabolites like WP1122, aimed at treating pathogenic viruses and certain cancer indications [5] Upcoming Events - The company will participate in the Corporate Connect Webinar Series hosted by Webull Financial on February 10-11, 2026, with a presentation by Walter Klemp, the Founder, President, CEO, and Chairman [1]

Core Viewpoint - Annamycin, a next-generation anthracycline, shows no evidence of cardiotoxicity in 90 subjects across five clinical trials, indicating its potential as a safer treatment option for various cancers [1][3]. Group 1: Clinical Trial Results - An independent assessment confirmed the absence of cardiotoxicity in subjects treated with Annamycin, with data reviewed from 90 subjects [1]. - The trials involved treating acute myeloid leukemia (AML) and soft tissue sarcoma (STS) with Annamycin as a monotherapy and in combination with cytarabine [1]. - Notably, 65 out of 90 subjects received doses exceeding the FDA's lifetime maximum of 550 mg/m², with one subject receiving over 6500 mg/m² [3]. Group 2: Safety and Efficacy Data - The assessment included data from serial 12-lead ECGs, echocardiography, and cardiac biomarker measurements, which are critical for evaluating potential heart damage [2]. - Annamycin is designed to avoid multidrug resistance mechanisms and lacks the cardiotoxicity associated with current anthracyclines [4]. Group 3: Future Development and Market Potential - The company has initiated the MIRACLE trial, a pivotal Phase 3 study evaluating Annamycin in combination with cytarabine for relapsed or refractory AML [5][6]. - The company believes that Annamycin could become the first non-cardiotoxic anthracycline, addressing a significant unmet medical need in cancer treatment [3]. - The potential market opportunity for Annamycin is substantial, given the high incidence of cardiotoxicity in existing cancer treatments [3].

Core Insights - The company has reported an increase in enrollment for the MIRACLE trial, reaching 78% of the target number of subjects for the first interim unblinding, up from 60% in November [1][2] - The trial aims to evaluate Annamycin in combination with cytarabine for treating adult patients with relapsed or refractory acute myeloid leukemia (AML) [1][9] - The first unblinding is expected to occur in the first quarter of 2026, with a target of 45 subjects [1][4] Enrollment and Trial Progress - As of December 3, 2025, the company has consented subjects from seven countries, indicating a diverse patient population [4] - The company anticipates completing treatment of the first 45 subjects by the first quarter of 2026 and aims to finish Part A of the trial with up to 90 patients in the first half of 2026 [4][2] - The trial design allows for unblinding of preliminary efficacy data at 45 subjects, with a focus on complete remission as a primary endpoint [3] Annamycin's Potential and Designation - Annamycin has received Fast Track Status and Orphan Drug Designation from the FDA for treating relapsed or refractory AML, as well as Orphan Drug Designation from the EMA [6][7] - The drug is designed to avoid multidrug resistance mechanisms and lacks the cardiotoxicity associated with current anthracyclines [8] - The company believes Annamycin could provide a safer and more effective treatment option for AML patients [2]